Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gz-389988. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 19/20 | 1.00 |
| ▸ | CSF1R | P07333 | 20/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 19/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gz-389988 SCHEMBL16762937 | 1.00 | CSF1R (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL29774374 | 1.00 | CSF1R (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL31167982 | 0.99 | CSF1R (0.98) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL17843975 | 0.99 | CSF1R (0.98) | CSF1RNTRK1NTRK2NTRK3 | |
| Gz-389988 SCHEMBL30387411 | 0.99 | CSF1R (0.98) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL29774452 | 0.92 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16763058 | 0.92 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16884597 | 0.90 | CSF1R (0.82) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16762913 | 0.90 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 | |
| SCHEMBL16762920 | 0.90 | NTRK1 (1.00) | CSF1RNTRK1NTRK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12527737-B2 | Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255875-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-4598633-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | The Brigham & Women's Hospital, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025128165-A2 | ELECTROPHILIC REACTIVE LINKERS FOR LABELING OF POLYPEPTIDES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2023092094-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230139639-A1 | SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-05-04 | — | — | US | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11560378-B2 | Treatment of osteoarthritis | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115626927-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-4110772-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022225728-A9 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022225728-A2 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11446288-B2 | Single-dose, ready-to-use injectable formulations | BIOSPLICE THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220110861-A1 | PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139639-A1 | SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS | UGT1A1, TTR, LPXN | NTRK1 1338/4885CSF1R 1494/4885NTRK2 3345/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | NTRK1 3/4885CSF1R 4155/4885NTRK2 21/4885 |
| US-11446288-B2 | Single-dose, ready-to-use injectable formulations | UGT1A1, TTR, LPXN | NTRK1 1338/4885CSF1R 1494/4885NTRK2 3345/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | NTRK1 4/4885CSF1R 2437/4885NTRK2 20/4885 |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | NTRK1 474/4885CSF1R 1724/4885NTRK2 1319/4885 |
| US-20250255875-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | NTRK1 474/4885CSF1R 1724/4885NTRK2 1319/4885 |
| US-11560378-B2 | Treatment of osteoarthritis | COL2A1, COL1A1, COL14A1 | NTRK1 4291/4885CSF1R 2147/4885NTRK2 1654/4885 |
| US-12527737-B2 | Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors | TPM3, TPM4, MATK | NTRK1 14/4885CSF1R 2820/4885NTRK2 32/4885 |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | ERBB2, ACP1, TK1 | NTRK1 474/4885CSF1R 1724/4885NTRK2 1319/4885 |
| US-20220110861-A1 | PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS | DMPK, MATK, MUSK | NTRK1 12/4885CSF1R 4119/4885NTRK2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.